Company news
Spago Nanomedical Ab (OMXSTO:SPAGO) news
Spago Nanomedical Ab news releases on 6ix. Latest, Sep 21, 2026: Notice Of Extraordinary General Meeting in Spago Nanomedical AB (PUBL)
Press releases & updates
Notice Of Extraordinary General Meeting in Spago Nanomedical AB (PUBL)
September 21, 2026
Spago Nanomedical Interim Report January-June 2026
August 20, 2026
Bulletin from the 2026 Annual General Meeting of Spago Nanomedical AB
June 10, 2026
The subscription period in Spago Nanomedical’s rights issue begins today
June 3, 2026
Spago Nanomedical publishes information document in connection with forthcoming rights issue
June 2, 2026
Spago Nanomedical: Raises capital
May 22, 2026
Spago Nanomedical resolves on a rights issue of approximately SEK 16 million
May 22, 2026
Spago Nanomedical's Phase I/IIa study Tumorad-01 Meets a Primary Endpoint and Provides Further Visible Tumor Uptake
May 6, 2026
Spago Nanomedical's Abstract on Tumorad(R) Accepted for Presentation at Radiopharma Conference
March 24, 2026
Spago Nanomedical Continues Recruitment in The Phase I/IIa Tumorad-01 Study Following Positive DMC Recommendation
March 17, 2026
Spago Nanomedical Strengthens CMC and Supply Capabilities to Support Next Phase of Tumorad Development
March 10, 2026
Spago Nanomedical Year-End Report January-December, 2025
February 5, 2026
Nomination Committee Appointed for Spago Nanomedical's Annual General Meeting 2026
December 8, 2025
Spago Nanomedical Announces Outcome of Oversubscribed Rights Issue
November 24, 2025
The Subscription Period in Spago Nanomedical's Rights Issue Begins Today
November 7, 2025
Spago Nanomedical Resolves on a Rights Issue of Approximately SEK 25 million to Advance Tumorad
October 29, 2025
Spago Nanomedical Interim Report January-September 2025
October 29, 2025
Visible Tumor Uptake and Recommended Dose Increase in Spago Nanomedicals's Phase I/IIa Study Tumorad-01
October 14, 2025
Spago Nanomedical Interim Report January-June, 2025
August 20, 2025
Spago Nanomedical Continues Patient Recruitment in the Phase I/IIa Study Tumorad-01 as Planned after DMC Recommendation
June 3, 2025
Bulletin from the 2025 Annual General Meeting of Spago Nanomedical AB
May 14, 2025
Spago Nanomedical Interim Report January-March, 2025
May 7, 2025